190 related articles for article (PubMed ID: 10999771)
1. In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells.
Zeng S; Chen YZ; Fu L; Johnson KR; Fan W
Clin Cancer Res; 2000 Sep; 6(9):3766-73. PubMed ID: 10999771
[TBL] [Abstract][Full Text] [Related]
2. Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2.
Berchem GJ; Bosseler M; Mine N; Avalosse B
Anticancer Res; 1999; 19(1A):535-40. PubMed ID: 10226594
[TBL] [Abstract][Full Text] [Related]
3. Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis.
Sui M; Xiong X; Kraft AS; Fan W
Cancer Biol Ther; 2006 Aug; 5(8):1015-21. PubMed ID: 16855376
[TBL] [Abstract][Full Text] [Related]
4. Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy.
Johnson KR; Young KK; Fan W
Clin Cancer Res; 1999 Sep; 5(9):2559-65. PubMed ID: 10499633
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel enhances the cytotoxicity of tetrahydropyranyladriamycin in a sequence-dependent manner.
Egawa T; Kubota T; Furukawa T; Otani Y; Watanabe M; Furukawa T; Kumai K; Kitajima M
Anticancer Res; 2001; 21(4A):2597-600. PubMed ID: 11724327
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
7. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells.
Johnson KR; Wang L; Miller MC; Willingham MC; Fan W
Clin Cancer Res; 1997 Oct; 3(10):1739-45. PubMed ID: 9815558
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle-dependent antagonistic interactions between paclitaxel and gamma-radiation in combination therapy.
Sui M; Dziadyk JM; Zhu X; Fan W
Clin Cancer Res; 2004 Jul; 10(14):4848-57. PubMed ID: 15269161
[TBL] [Abstract][Full Text] [Related]
9. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
[TBL] [Abstract][Full Text] [Related]
10. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
[TBL] [Abstract][Full Text] [Related]
11. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.
Itoh K; Sasaki Y; Fujii H; Minami H; Ohtsu T; Wakita H; Igarashi T; Watanabe Y; Onozawa Y; Kashimura M; Ohashi Y
Clin Cancer Res; 2000 Oct; 6(10):4082-90. PubMed ID: 11051260
[TBL] [Abstract][Full Text] [Related]
12. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Sparano JA
Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel in combination chemotherapy for metastatic breast cancer.
Khayat D; Antoine E
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
[TBL] [Abstract][Full Text] [Related]
14. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
Cardoso F; Ferreira Filho AF; Crown J; Dolci S; Paesmans M; Riva A; Di Leo A; Piccart MJ
Anticancer Res; 2001; 21(1B):789-95. PubMed ID: 11299845
[TBL] [Abstract][Full Text] [Related]
16. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
Prados J; Melguizo C; Rama AR; Ortiz R; Segura A; Boulaiz H; Vélez C; Caba O; Ramos JL; Aránega A
Cancer Chemother Pharmacol; 2010 May; 66(1):69-78. PubMed ID: 19771430
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel enhances the cytotoxicity of anthracyclines by increasing intracellular drug accumulation.
Egawa T; Kubota T; Suto A; Otani Y; Furukawa T; Watanabe M; Kumai K; Kitajima M
Oncol Rep; 2002; 9(4):777-81. PubMed ID: 12066208
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
